Evotec SE Stock

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 11:41:54 2024-04-24 am EDT After market 01:28:00 pm
9.64 EUR -32.02% Intraday chart for Evotec SE 9.64 0.00%
Sales 2023 781M 835M Sales 2024 * 935M 999M Capitalization 2.51B 2.69B
Net income 2023 * -54M -57.71M Net income 2024 * 31M 33.13M EV / Sales 2023 4.82 x
Net cash position 2023 * 46.3M 49.48M Net cash position 2024 * 37M 39.54M EV / Sales 2024 * 2.65 x
P/E ratio 2023 *
-46.6 x
P/E ratio 2024 *
78 x
Employees 5,086
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Evotec SE

1 day-31.95%
1 week-27.02%
Current month-33.38%
1 month-28.49%
3 months-35.73%
6 months-42.08%
Current year-54.70%
More quotes
1 week
8.52
Extreme 8.52
14.22
1 month
8.52
Extreme 8.52
14.77
Current year
8.52
Extreme 8.52
21.42
1 year
8.52
Extreme 8.52
24.44
3 years
8.52
Extreme 8.52
45.83
5 years
8.52
Extreme 8.52
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-06-18
Director of Finance/CFO 51 23-02-06
Chief Operating Officer 54 12-04-30
Members of the board TitleAgeSince
Chief Executive Officer 61 19-06-18
Director/Board Member 56 19-06-18
Chairman 63 14-06-16
More insiders
Date Price Change Volume
24-04-24 9.64 -32.02% 21 191 178
24-04-23 14.18 +3.50% 654,746
24-04-22 13.7 +3.32% 725,516
24-04-19 13.26 -1.41% 673,258
24-04-18 13.45 +1.82% 694,213

Delayed Quote Xetra, April 24, 2024 at 11:41 am EDT

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.18 EUR
Average target price
25.4 EUR
Spread / Average Target
+79.13%
Consensus